Compile Data Set for Download or QSAR
maximum 50k data
Found 40 Enz. Inhib. hit(s) with all data for entry = 9015
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM435491(US10570125, Example 1 | US11084810, Example 1 | US...)
Affinity DataEC50:  18nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295702(US10112934, Example 8 | US10570125, Example 8 | US...)
Affinity DataEC50:  6.90E+4nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM435493(US10570125, Example 7 | US11084810, Example 7 in W...)
Affinity DataEC50:  15nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM435493(US10570125, Example 7 | US11084810, Example 7 in W...)
Affinity DataEC50:  2.80E+4nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM435502(US10570125, Example 134 | US11084810, Example 134 ...)
Affinity DataEC50:  49nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM435502(US10570125, Example 134 | US11084810, Example 134 ...)
Affinity DataEC50:  2.60E+4nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295673(US10112934, Example 2 | US10570125, Example 2 | US...)
Affinity DataEC50:  104nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295673(US10112934, Example 2 | US10570125, Example 2 | US...)
Affinity DataEC50: >2.00E+5nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM435491(US10570125, Example 1 | US11084810, Example 1 | US...)
Affinity DataEC50:  88nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM435491(US10570125, Example 1 | US11084810, Example 1 | US...)
Affinity DataEC50: >5.00E+4nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295688(Example 17 in WO2010036630 | US10570125, Example 1...)
Affinity DataEC50:  30nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295688(Example 17 in WO2010036630 | US10570125, Example 1...)
Affinity DataEC50:  8.60E+3nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295689(US10112934, Example 3 | US10570125, Example 3 | US...)
Affinity DataEC50:  8nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295689(US10112934, Example 3 | US10570125, Example 3 | US...)
Affinity DataEC50: >2.00E+5nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295673(US10112934, Example 2 | US10570125, Example 2 | US...)
Affinity DataEC50:  11nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295673(US10112934, Example 2 | US10570125, Example 2 | US...)
Affinity DataEC50:  1.50E+5nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295691(Example 38 in WO2010036630 | US10570125, Example 3...)
Affinity DataEC50:  3.10nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295691(Example 38 in WO2010036630 | US10570125, Example 3...)
Affinity DataEC50:  5.00E+4nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295692(Example 133 in WO2010036630 | US10570125, Example ...)
Affinity DataEC50:  140nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295692(Example 133 in WO2010036630 | US10570125, Example ...)
Affinity DataEC50: >2.00E+5nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295693(US10112934, Example 4 | US10570125, Example 4 | US...)
Affinity DataEC50:  0.360nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295693(US10112934, Example 4 | US10570125, Example 4 | US...)
Affinity DataEC50:  3.94E+4nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295694(Example 46 in WO2010147792 | US10570125, Example 4...)
Affinity DataEC50:  0.270nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295694(Example 46 in WO2010147792 | US10570125, Example 4...)
Affinity DataEC50:  923nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM435493(US10570125, Example 7 | US11084810, Example 7 in W...)
Affinity DataEC50:  25nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM435493(US10570125, Example 7 | US11084810, Example 7 in W...)
Affinity DataEC50: >2.00E+5nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295696(US10112934, Example 5 | US10570125, Example 5 | US...)
Affinity DataEC50:  0.230nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295696(US10112934, Example 5 | US10570125, Example 5 | US...)
Affinity DataEC50:  2.50E+3nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295697(Example 47 in WO2010147792 | US10570125, Example 4...)
Affinity DataEC50:  0.850nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295697(Example 47 in WO2010147792 | US10570125, Example 4...)
Affinity DataEC50:  3.10E+3nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295698(US10112934, Example 6 | US10570125, Example 6 | US...)
Affinity DataEC50:  11nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295698(US10112934, Example 6 | US10570125, Example 6 | US...)
Affinity DataEC50:  8.70E+4nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM50042659(CHEMBL3353870 | Example 190 in WO2010077836 | US10...)
Affinity DataEC50:  2.80nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM50042659(CHEMBL3353870 | Example 190 in WO2010077836 | US10...)
Affinity DataEC50:  7.87E+3nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM435493(US10570125, Example 7 | US11084810, Example 7 in W...)
Affinity DataEC50:  25nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM435493(US10570125, Example 7 | US11084810, Example 7 in W...)
Affinity DataEC50: >2.00E+5nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295701(Example 30 in WO2010147792 | US10570125, Example 3...)
Affinity DataEC50:  5.40nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295701(Example 30 in WO2010147792 | US10570125, Example 3...)
Affinity DataEC50:  1.20E+5nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM295702(US10112934, Example 8 | US10570125, Example 8 | US...)
Affinity DataEC50:  4.30nMAssay Description:CB2: CHO cells expressing human CB2R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM435491(US10570125, Example 1 | US11084810, Example 1 | US...)
Affinity DataEC50:  1.04E+5nMAssay Description:CB1: CHO cells expressing human CB1R (Euroscreen) were plated at a density of 10,000 cells per well in 384 well plates and incubated overnight at 37°...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent